ClinicalTrials.gg

Program

clemizole hydrochloride

Also written as “Clemizole HCl”, “EPX-100” and “EPX-100 (Clemizole Hydrochloride)”.

Its studies are mostly in Epilepsies, Myoclonic · Lennox Gastaut Syndrome · Hepatitis C · Carcinoma, Hepatocellular, led by 3 companies.

Furthest: phase 3, since Jul 6, 20207 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Epygenix53 open or runningphase 3since Jul 6, 2020Aug 22, 2019Dec 30, 2026phase 1 · NCT07879170
Eiger BioPharmaceuticals10 open or runningphase 1since Jul 23, 2009Jul 23, 2009none ahead
Eiger Group International10 open or runningphase 2since Feb 14, 2017Feb 14, 2017none ahead

Also a collaborator on its studies: Harmony Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2009First study: phase 1 study in Hepatitis CNew to Eiger BioPharmaceuticalsEiger BioPharmaceuticals · NCT00945880 · 12 enrolled
  2. Feb 14, 2017Eiger Group International’s first study: phase 2 study in Carcinoma, HepatocellularNew to Eiger Group InternationalEiger Group International · NCT03069508 · 12 enrolled · Turkey
  3. Aug 22, 2019Epygenix’s first study: phase 1 study in Epilepsies, MyoclonicNew to EpygenixEpygenix · NCT04069689 · 24 enrolled · United States
  4. Jul 6, 2020Phase 3 study in Epilepsies, MyoclonicEpygenix · NCT04462770 · 150 planned · United States, Argentina, Brazil and more
  5. Sep 23, 2021Phase 3 study in Lennox Gastaut SyndromeEpygenix · NCT05066217 · 260 planned · United States, China, Hungary and more
  6. Sep 11, 20262 phase 1 studiesEpygenix · NCT07824193, NCT07879170

Ahead

  1. Nov 1, 2026Primary completion: phase 3 study in Lennox Gastaut SyndromeEpygenix · NCT05066217
  2. Dec 30, 2026Primary completion: phase 1 study in Healthy ParticipantsEpygenix · NCT07879170
  3. Apr 2027Primary completion: phase 3 study in Epilepsies, MyoclonicEpygenix · NCT04462770

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07879170Healthy Participants · United States1RecruitingEpygenixDec 30, 202688
NCT07824193Drug Drug Interaction · United States1CompletedEpygenixApr 3, 202554
NCT05066217Lennox Gastaut Syndrome · United States, China, Hungary and more3RecruitingEpygenixNov 1, 2026260
NCT04462770Epilepsies, Myoclonic · United States, Argentina, Brazil and more3RecruitingEpygenixApr 2027150
NCT04069689Epilepsies, Myoclonic · United States1CompletedEpygenixNov 27, 201924
NCT03069508Carcinoma, Hepatocellular · Turkey2UNKNOWNEiger Group InternationalDec 31, 201712
NCT00945880Hepatitis C1CompletedEiger BioPharmaceuticalsAug 201012

How it is read

Names in the registry

  • “Clemizole HCl”, 2 entries
  • “EPX-100”, 2 entries
  • “EPX-100 (Clemizole Hydrochloride)”, 1 entry
  • “clemizole hydrochloride”, 1 entry
  • “Clemizole Hydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.